PET imaging studying [11C]C-erlotinib in glioma xenografts showed specific binding of the radiopharmaceutical for activating mutations of the kinase domain but no specific binding for activating mutations of the extracellular domain of the EGFR [132]. This evidence concerns the gene EGFR and central nervous system cancer.